Transcriptomics

Dataset Information

0

Harnessing Features of Adaptive NK Cells to Generate iPSC-Derived NK Cells for Enhanced Immunotherapy


ABSTRACT: Cell-based immunotherapy can control bulky tumors, but effector cell persistence, tumor resistance, inconsistencies of the manufactured product, and treatment cost continue to pose challenges. To address these limitations, we developed a triple gene-edited induced pluripotent stem cell (iPSC) platform for broad patient-based adoptive cell therapy. iPSCs were engineered to express a high affinity, non-cleavable version of the Fc receptor CD16a to augment antibody-mediated activity and a membrane-bound IL-15/IL-15R fusion (IL-15RF) protein to promote survival and maturation. The third edit was knockout of the ecto-enzyme CD38 that hydrolyzes NAD+ and is the target of the therapeutic antibody daratumumab. Natural killer (NK) cells derived from these iPSCs displayed metabolic features and gene expression profiles similar to those of adaptive NK cells that arise in response to cytomegalovirus (CMV) infection. These engineered iPSC-derived NK cells, termed iADAPT, persisted in vivo in the absence of exogenous cytokine and could be combined with daratumumab for efficient killing of multiple myeloma and acute myeloid leukemia cells both in vitro and in vivo. This strategy has broad off-the-shelf potential for the treatment of patients with advanced cancer.

ORGANISM(S): Homo sapiens

PROVIDER: GSE168936 | GEO | 2021/03/16

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2023-03-01 | GSE212796 | GEO
2024-04-08 | GSE263459 | GEO
2024-07-09 | GSE227098 | GEO
2022-10-14 | PXD027284 | Pride
2016-09-21 | GSE45612 | GEO
2020-05-09 | GSE150155 | GEO
2020-04-06 | PXD011672 | Pride
2021-08-01 | GSE155795 | GEO
2021-09-09 | PXD018982 | Pride
2020-05-13 | GSE150363 | GEO